Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kendra Butner

Nurse Practitioner, Family Higginsville, MO Nurse Practitioner

NPI 1609958891 CMS profile 1396291

1200 W 22Nd St, Higginsville, MO 64037

Open in the dashboard

General payments

$34,834

453 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kendra Butner of Higginsville, MO is reported in the CMS Open Payments database as having received $34,834 across 453 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,831 88
2024 General $12,114 90
2023 General $3,158 82
2022 General $3,283 112
2021 General $1,449 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kendra Butner
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kendra Butner were reported at $14,831. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kendra Butner Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,449 $124 $35–$379 $132
2022 $3,283 $141 $44–$430 $149
2023 $3,158 $154 $49–$476 $160
2024 $12,114 $165 $51–$504 $164
2025 $14,831 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Tandem Diabetes Care, Inc. $20,618 26 payments
  2. Lilly USA, LLC $3,432 53 payments
  3. Insulet Corporation $2,199 16 payments
  4. AbbVie, Inc. $1,632 88 payments
  5. AstraZeneca Pharmaceuticals LP $1,427 58 payments
  6. Amgen Inc. $923 27 payments
  7. Dexcom, Inc. $723 21 payments
  8. Medtronic, Inc. $556 5 payments
  9. Novo Nordisk Inc $543 34 payments
  10. Abbott Laboratories $374 15 payments
  11. Other $2,405 110 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,220 29 payments
  2. Food and Beverage $9,816 414 payments
  3. Consulting Fee $2,500 3 payments
  4. Travel and Lodging $132 3 payments
  5. Education $107 3 payments
  6. Gift $59 1 payment
Products named General payments · program years 2021–2025
  1. t:slim X2 Insulin Pump with Control-IQ $20,597 25 payments
  2. Omnipod $2,199 16 payments
  3. MOUNJARO $1,142 20 payments
  4. FARXIGA $674 33 payments
  5. VRAYLAR $667 29 payments
  6. AIRSUPRA $596 15 payments
  7. Repatha $528 16 payments
  8. QULIPTA $520 34 payments
  9. Dexcom G6 Transmitter $494 17 payments
  10. UBRELVY $478 28 payments
  11. Other $6,836 330 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

3,762

Median for Nurse Practitioner: 389

Drug cost

$484,995

Median for Nurse Practitioner: $21,885

Branded share of claims

26.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 103 $125,040
Jardiance Empagliflozin Brand 64 $78,547
Farxiga Dapagliflozin Propanediol Brand 40 $40,512
Trulicity Dulaglutide Brand 28 $33,826
Afrezza Insulin Regular, Human Brand 18 $32,494
Mounjaro Tirzepatide Brand 24 $25,594
Xarelto Rivaroxaban Brand 19 $20,192
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 42 $19,986
Myrbetriq Mirabegron Brand 16 $14,740
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $12,473

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $226
$226 — —
Repatha
  • Amgen Inc. $160
$160 11 —
JARDIANCE
  • Lilly USA, LLC $157
$157 64 —
VRAYLAR
  • AbbVie, Inc. $139
$139 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

453 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record